Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination.

Yates NL, Liao HX, Fong Y, deCamp A, Vandergrift NA, Williams WT, Alam SM, Ferrari G, Yang ZY, Seaton KE, Berman PW, Alpert MD, Evans DT, O'Connell RJ, Francis D, Sinangil F, Lee C, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, Pinter A, Zolla-Pazner S, Gilbert PB, Nabel GJ, Michael NL, Kim JH, Montefiori DC, Haynes BF, Tomaras GD.

Sci Transl Med. 2014 Mar 19;6(228):228ra39. doi: 10.1126/scitranslmed.3007730.

2.

Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens.

Karnasuta C, Akapirat S, Madnote S, Savadsuk H, Puangkaew J, Rittiroongrad S, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Tartaglia J, Sinangil F, Francis DP, Robb ML, de Souza MS, Michael NL, Excler JL, Kim JH, O'Connell RJ, Karasavvas N.

AIDS Res Hum Retroviruses. 2017 May;33(5):410-423. doi: 10.1089/AID.2016.0204. Epub 2017 Jan 30.

3.

Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines.

Chung AW, Ghebremichael M, Robinson H, Brown E, Choi I, Lane S, Dugast AS, Schoen MK, Rolland M, Suscovich TJ, Mahan AE, Liao L, Streeck H, Andrews C, Rerks-Ngarm S, Nitayaphan S, de Souza MS, Kaewkungwal J, Pitisuttithum P, Francis D, Michael NL, Kim JH, Bailey-Kellogg C, Ackerman ME, Alter G.

Sci Transl Med. 2014 Mar 19;6(228):228ra38. doi: 10.1126/scitranslmed.3007736.

4.

Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.

Gottardo R, Bailer RT, Korber BT, Gnanakaran S, Phillips J, Shen X, Tomaras GD, Turk E, Imholte G, Eckler L, Wenschuh H, Zerweck J, Greene K, Gao H, Berman PW, Francis D, Sinangil F, Lee C, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, Robb ML, Michael NL, Kim JH, Zolla-Pazner S, Haynes BF, Mascola JR, Self S, Gilbert P, Montefiori DC.

PLoS One. 2013 Sep 26;8(9):e75665. doi: 10.1371/journal.pone.0075665. eCollection 2013.

5.

Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses.

Tay MZ, Liu P, Williams LD, McRaven MD, Sawant S, Gurley TC, Xu TT, Dennison SM, Liao HX, Chenine AL, Alam SM, Moody MA, Hope TJ, Haynes BF, Tomaras GD.

PLoS Pathog. 2016 Aug 31;12(8):e1005817. doi: 10.1371/journal.ppat.1005817. eCollection 2016 Aug.

6.

Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines.

Excler JL, Ake J, Robb ML, Kim JH, Plotkin SA.

Clin Vaccine Immunol. 2014 Aug;21(8):1023-36. doi: 10.1128/CVI.00230-14. Epub 2014 Jun 11. Review.

7.

HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities.

Pollara J, Bonsignori M, Moody MA, Liu P, Alam SM, Hwang KK, Gurley TC, Kozink DM, Armand LC, Marshall DJ, Whitesides JF, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Robb ML, O'Connell RJ, Kim JH, Michael NL, Montefiori DC, Tomaras GD, Liao HX, Haynes BF, Ferrari G.

J Virol. 2014 Jul;88(14):7715-26. doi: 10.1128/JVI.00156-14. Epub 2014 May 7.

8.

Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses.

Fouda GG, Cunningham CK, McFarland EJ, Borkowsky W, Muresan P, Pollara J, Song LY, Liebl BE, Whitaker K, Shen X, Vandergrift NA, Overman RG, Yates NL, Moody MA, Fry C, Kim JH, Michael NL, Robb M, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Liao HX, Haynes BF, Montefiori DC, Ferrari G, Tomaras GD, Permar SR.

J Infect Dis. 2015 Feb 15;211(4):508-17. doi: 10.1093/infdis/jiu444. Epub 2014 Aug 27.

9.

Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2.

Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-Buell E, Hertz T, deCamp AC, Carrico C, Menis S, Magaret CA, Ahmed H, Juraska M, Chen L, Konopa P, Nariya S, Stoddard JN, Wong K, Zhao H, Deng W, Maust BS, Bose M, Howell S, Bates A, Lazzaro M, O'Sullivan A, Lei E, Bradfield A, Ibitamuno G, Assawadarachai V, O'Connell RJ, deSouza MS, Nitayaphan S, Rerks-Ngarm S, Robb ML, McLellan JS, Georgiev I, Kwong PD, Carlson JM, Michael NL, Schief WR, Gilbert PB, Mullins JI, Kim JH.

Nature. 2012 Oct 18;490(7420):417-20. doi: 10.1038/nature11519. Epub 2012 Sep 10.

10.

Prospects for a globally effective HIV-1 vaccine.

Excler JL, Robb ML, Kim JH.

Vaccine. 2015 Nov 27;33 Suppl 4:D4-12. doi: 10.1016/j.vaccine.2015.03.059. Epub 2015 Jun 20. Review.

PMID:
26100921
11.

IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens.

Karasavvas N, Karnasuta C, Savadsuk H, Madnote S, Inthawong D, Chantakulkij S, Rittiroongrad S, Nitayaphan S, Pitisuttithum P, Thongcharoen P, Siriyanon V, Andrews CA, Barnett SW, Tartaglia J, Sinangil F, Francis DP, Robb ML, Michael NL, Ngauy V, de Souza MS, Paris RM, Excler JL, Kim JH, O'Connell RJ; MOPH-TAVEG Collaboration.

AIDS Res Hum Retroviruses. 2015 Nov;31(11):1178-86. doi: 10.1089/AID.2015.0034. Epub 2015 Sep 9.

12.

Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection.

Kim JH, Excler JL, Michael NL.

Annu Rev Med. 2015;66:423-37. doi: 10.1146/annurev-med-052912-123749. Epub 2014 Oct 17. Review.

PMID:
25341006
13.

Immune-correlates analysis of an HIV-1 vaccine efficacy trial.

Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, Berman PW, Frahm N, De Rosa SC, Alpert MD, Yates NL, Shen X, Koup RA, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael NL, Kim JH.

N Engl J Med. 2012 Apr 5;366(14):1275-86. doi: 10.1056/NEJMoa1113425.

14.

Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection.

Zolla-Pazner S, deCamp A, Gilbert PB, Williams C, Yates NL, Williams WT, Howington R, Fong Y, Morris DE, Soderberg KA, Irene C, Reichman C, Pinter A, Parks R, Pitisuttithum P, Kaewkungwal J, Rerks-Ngarm S, Nitayaphan S, Andrews C, O'Connell RJ, Yang ZY, Nabel GJ, Kim JH, Michael NL, Montefiori DC, Liao HX, Haynes BF, Tomaras GD.

PLoS One. 2014 Feb 4;9(2):e87572. doi: 10.1371/journal.pone.0087572. eCollection 2014.

15.

Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial.

Gartland AJ, Li S, McNevin J, Tomaras GD, Gottardo R, Janes H, Fong Y, Morris D, Geraghty DE, Kijak GH, Edlefsen PT, Frahm N, Larsen BB, Tovanabutra S, Sanders-Buell E, deCamp AC, Magaret CA, Ahmed H, Goodridge JP, Chen L, Konopa P, Nariya S, Stoddard JN, Wong K, Zhao H, Deng W, Maust BS, Bose M, Howell S, Bates A, Lazzaro M, O'Sullivan A, Lei E, Bradfield A, Ibitamuno G, Assawadarachai V, O'Connell RJ, deSouza MS, Nitayaphan S, Rerks-Ngarm S, Robb ML, Sidney J, Sette A, Zolla-Pazner S, Montefiori D, McElrath MJ, Mullins JI, Kim JH, Gilbert PB, Hertz T.

J Virol. 2014 Aug;88(15):8242-55. doi: 10.1128/JVI.01164-14. Epub 2014 May 14.

16.

Novel directions in HIV-1 vaccines revealed from clinical trials.

Excler JL, Tomaras GD, Russell ND.

Curr Opin HIV AIDS. 2013 Sep;8(5):421-31. doi: 10.1097/COH.0b013e3283632c26. Review.

17.

Prospects for a Globally Effective HIV-1 Vaccine.

Excler JL, Robb ML, Kim JH.

Am J Prev Med. 2015 Dec;49(6 Suppl 4):S307-18. doi: 10.1016/j.amepre.2015.09.004. Review.

PMID:
26590431
18.

The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope.

de Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S, Nuntapinit B, Valencia-Micolta A, Thelian D, Nitayaphan S, Pitisuttithum P, Paris RM, Kaewkungwal J, Michael NL, Rerks-Ngarm S, Mathieson B, Marovich M, Currier JR, Kim JH; Ministry of Public Health–Thai AIDS Vaccine Evaluation Group Collaborators.

J Immunol. 2012 May 15;188(10):5166-76. doi: 10.4049/jimmunol.1102756. Epub 2012 Apr 23.

19.

HIV vaccine efficacy and immune correlates of risk.

O'Connell RJ, Excler JL.

Curr HIV Res. 2013 Sep;11(6):450-63. Review.

PMID:
24033301
20.

Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide.

Rolland M, Gilbert P.

AIDS Res Hum Retroviruses. 2012 Apr;28(4):400-4. doi: 10.1089/AID.2011.0240. Epub 2011 Sep 27.

Supplemental Content

Support Center